Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
Department of Translational Neuroscience, Wake Forest University School of Medicine, Atrium Wake Forest Baptist Health, Winston-Salem, NC 27101, United States.
Brain Behav Immun. 2024 Nov;122:137-149. doi: 10.1016/j.bbi.2024.08.003. Epub 2024 Aug 3.
Cocaine use disorder is a condition that leads to tremendous morbidity and mortality for which there are currently no FDA-approved pharmacotherapies. Previous research has demonstrated an important role for the resident population of bacteria of the large intestine, collectively dubbed the gut microbiome, in modulating brain and behavior in models of cocaine and other substance use disorders. Importantly, previous work has repeatedly shown that depletion of the gut microbiome leads to increased cocaine taking and seeking behaviors in multiple models. While the precise mechanism of these gut-brain signaling pathways in models of cocaine use is not fully clear, and intriguing possibility is through gut microbiome influences on innate immune system function. In this manuscript we identify the cytokine colony stimulating factor 2 (CSF2) as an immune factor that is increased by cocaine in a gut microbiome dependent manner. Peripherally injected CSF2 crosses the blood-brain barrier into the nucleus accumbens, a brain region central to behavioral responses to cocaine. Treatment with peripheral CSF2 reduces acute and sensitized locomotor responses to cocaine as well as reducing cocaine place preference at high doses. On a molecular level, we find that peripheral injections of CSF2 alter the transcriptional response to both acute and repeated cocaine in the nucleus accumbens. Finally, treatment of microbiome depleted mice with CSF2 reverses the behavioral effects of microbiome depletion on the conditioned place preference assay. Taken together, this work identifies an innate immune factor that represents a novel gut-brain signaling cascade in models of cocaine use and lays the foundations for further translational work targeting this pathway.
可卡因使用障碍是一种导致极高发病率和死亡率的疾病,但目前尚无美国食品和药物管理局批准的药物治疗方法。先前的研究表明,大肠中常驻细菌群体(统称为肠道微生物组)在调节可卡因和其他物质使用障碍模型中的大脑和行为方面起着重要作用。重要的是,先前的工作反复表明,肠道微生物组的耗竭会导致多种模型中可卡因的摄取和寻求行为增加。虽然可卡因使用模型中这些肠道-大脑信号通路的确切机制尚不完全清楚,但一个有趣的可能性是通过肠道微生物组对先天免疫系统功能的影响。在本手稿中,我们确定细胞因子集落刺激因子 2 (CSF2) 作为一种免疫因子,它以依赖肠道微生物组的方式被可卡因增加。外周注射的 CSF2 穿过血脑屏障进入伏隔核,这是对可卡因行为反应的关键脑区。用外周 CSF2 治疗可减少急性和敏化的可卡因运动反应,并在高剂量时减少可卡因位置偏好。在分子水平上,我们发现外周注射 CSF2 改变了伏隔核中对急性和重复可卡因的转录反应。最后,用 CSF2 治疗肠道微生物组耗竭的小鼠可逆转肠道微生物组耗竭对条件位置偏好试验的行为影响。总之,这项工作确定了一种先天免疫因子,它代表了可卡因使用模型中的一种新的肠道-大脑信号级联,并为针对该途径的进一步转化工作奠定了基础。